Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · iShares

iShares Biotechnology ETF (IBB)

Ticker IBB · Since 2001-02-05 · · Holdings as of Sep 30, 2025

Expense ratio
0.44%$44/yr per $10k
5-yr return
+2.5%annualized
1-yr return
+28.0%as of Dec 2025
Net assets
$5.9Ball share classes
Holdings
254

Bottom line

Is IBB a good fund? The bottom line

IBB is an actively managed technology sector ETF from iShares.

It charges 0.44% — about $44 a year on every $10,000 invested, cheaper than 86% of technology sector funds we track.

It returned +28.0% over one year, +2.5% a year over five years, +4.4% a year over ten (as of Dec 31, 2025, per its prospectus).

With $5.9 billion in net assets and 254 holdings, its largest position is BlackRock Funds III (13.2%) and the top 10 make up 59% of the portfolio.

The closest lower-cost alternative we found is IBBQ (0.19%, 56% top-holdings overlap).

What stands out

  • Low cost: cheaper than 86% of technology sector peers
  • Broadly diversified (254 holdings)

What to watch

  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 59% of assets

Updated Nov 19, 2026

What IBB invests in

The iShares Biotechnology ETF (the Fund ) seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.

The Fund seeks to track the investment results of the NYSE Biotechnology Index (the Underlying Index ), which measures the performance of U.S.-listed securities of companies that are classified according to the ICE Uniform Sector Classification schema within the Biotechnology Sub-Industry Group (as determined by ICE Data Indices, LLC or its affiliates (collectively Index Provider or IDI )) and that also meet other eligibility criteria determined by the Index Provider, including minimum market capitalization and liquidity requirements. Companies classified within the Biotechnology Sub-Industry Group include those companies that are engaged in the research and development of therapeutic treatments but that are not focused on the commercialization and mass production of pharmaceutical drugs. The Biotechnology Sub-Industry Group also includes those companies that are engaged in the…

From the fund's prospectus (filed Jul 27, 2026).

IBB performance

Fund calendar-year total returns, 2015–2025 2015: +11.5%; 2016: −21.5%; 2017: +21.2%; 2018: −9.1%; 2019: +24.8%; 2020: +25.9%; 2021: +1.0%; 2022: −13.6%; 2023: +3.6%; 2024: −2.4%; 2025: +28.0% +11% 2015 −22% 2016 +21% 2017 −9% 2018 +25% 2019 +26% 2020 +1% 2021 −14% 2022 +4% 2023 −2% 2024 +28% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
IBB+28.0%+2.5%+4.4%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full IBB performance history →

What IBB costs

On a $10,000 investment, IBB's 0.44% expense ratio costs about $44 a year. The prospectus estimates $555 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full IBB fee table →

IBB top 10 holdings

#Holding% of fund
1BlackRock Funds III13.18%
2Vertex Pharmaceuticals, Inc.7.66%
3Gilead Sciences, Inc.7.52%
4Amgen, Inc.7.50%
5Regeneron Pharmaceuticals, Inc.5.70%
6Alnylam Pharmaceuticals, Inc.5.68%
7IQVIA Holdings, Inc.3.18%
8Argenx SE3.15%
9Insmed, Inc.2.95%
10Mettler-Toledo International, Inc.2.49%

Source: SEC Form N-PORT, period ended Sep 30, 2025

The top 10 make up 59% of the fund. See all top 25 holdings and asset mix →

Alternatives to IBB

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
InvescoIBBQ Invesco Nasdaq Biotechnology ETF0.19%56% Compare

More funds like IBB →

IBB FAQ

What is the expense ratio of IBB?
IBB's expense ratio is 0.44%, which works out to about $44 a year for every $10,000 invested. The prospectus estimates total costs of $555 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is IBB a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 86% of technology sector peers; broadly diversified (254 holdings); 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 59% of assets. This is general information, not personalized advice.
What does IBB hold?
IBB's largest holdings are BlackRock Funds III (13.2%), Vertex Pharmaceuticals, Inc. (7.7%), Gilead Sciences, Inc. (7.5%), Amgen, Inc. (7.5%), Regeneron Pharmaceuticals, Inc. (5.7%). It holds 254 positions in total as of Sep 30, 2025 (SEC Form N-PORT).
What is IBB's 5-year return?
IBB returned +2.5% a year over the five years ending Dec 31, 2025, and +4.4% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to IBB?
IBBQ (Invesco Nasdaq Biotechnology ETF) overlaps about 56% with IBB and charges 0.19%.
Who manages IBB?
IBB is offered by iShares through iSHARES TRUST.